Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
microRNA-199a
- Development stage
- Preclinical
- Modality
- miRNA Mimics → MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Topical
01
Overview
microRNA-199a (miR-199a) is a highly conserved microRNA family that plays a critical role in regulating gene expression post-transcriptionally across various physiological and pathological contexts, including oncology, cardiovascular disease, and metabolic disorders. It exists as two mature strands, miR-199a-3p and miR-199a-5p, which target distinct sets of mRNAs. In therapeutic development, synthetic miR-199a mimics are investigated for their ability to restore downregulated levels in diseases like hepatocellular carcinoma and ischemic stroke, where they often act as tumor suppressors or neuroprotective agents. Conversely, antagomirs or inhibitors targeting miR-199a are explored for conditions where the microRNA is overexpressed, such as in certain models of insulin resistance. miR-199a modulates key signaling pathways, including the PI3K/Akt/mTOR and NF-κB cascades, by directly binding to the 3' untranslated regions of target genes such as SIRT1, SCD1, and DDIT4.
- Other names
- microRNA 199amicroRNA199amicroRNA-199a
02
Targets
FZD4 (Frizzled class receptor 4)HIF1A (Hypoxia-inducible factor 1-alpha)JAG1 (Jagged-1 protein)WNT2 (Wnt family member 2)B7-H3CAPRIN1 (Cell cycle associated protein 1)DDIT4 (Regulated in development and DNA damage response protein 1)DDR1 (Discoidin domain receptor 1)PIK3R2 (PI3K regulatory subunit beta)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)SFRP5 (Secreted frizzled-related protein 5)SIRT1 (NAD-dependent protein deacetylase sirtuin-1)SCD1 (Stearoyl-CoA desaturase 1)
Beyond the preview
Go deeper on microRNA-199a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on microRNA-199a.